2 January 2024 in Pediatric Rheumatology
Background: Juvenile Dermatomyositis (JDM) is a rare autoimmune disorder that primarily affects muscles and skin. One of the severe complications associated with JDM is calcinosis, and treating this condition presents significant challenges. This study aimed to evaluate the efficacy and safety of local injection of infliximab into calcinosis lesions in patients with JDM. Methods: In this clinical trial, five patients diagnosed with JDM and calcinosis lesions were enrolled. The primary treatment consisted of weekly infliximab injections for 16 weeks, targeting all four sides of each lesion. Lesion dimensions, including length and width, were documented and monitored weekly. Before the intervention, patients underwent radiographic imaging. After the final injection in week 16, a follow-up radiographic assessment was performed. Data were analyzed using the Generalized Estimating Equation (GEE) method. Results: The lesions’ size significantly decreased in both length and width during each visit. On average, the lesion length reduced by 2.66%, and the width shrank by 3.32% per visit. Based on radiographic findings, the average length and width of lesions at the initial visit were 12.09 ± 5.05 mm (range: 6.00-25.50 mm) and 6.35 ± 3.00 mm (range: 2.00–16.00 mm), respectively. The average length and width at the last visit were 5.59 ± 7.05 mm (range: 0–23.00 mm) and 3.41 ± 4.05 mm (range: 0–13.00 mm), respectively. No specific side effects related to the treatment were reported. Conclusions: The results suggest that the direct administration of infliximab into the calcinosis lesions of patients with JDM could be a safe and effective treatment approach. Trial registration: Name of the registry: The effect of infliximab injection into calcinosis lesions on patients with juvenile dermatomyositis (JDM), Trial registration number: IRCT20210808052107N1, Registration date: 2022-07-22, URL of trial registry record: https://en.irct.ir/trial/58329.
19 August 2025 in BMC Musculoskeletal Disorders
Camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome is an inherited autosomal recessive disorder resulting from a mutation in the PRG4 gene located on chromosome one. This mutation leads to either a deficiency or dysfunction of a glycoprotein known as lubricin, which plays a crucial role in inhibiting synovial inflammation and lubricating synovial joints and visceral cavities. CACP syndrome is characterized by a tetrad of manifestations, including congenital or early-onset camptodactyly, childhood-onset non-inflammatory arthropathy accompanied by synovial hyperplasia, coxa vara deformity, and non-inflammatory pericardial effusion. This case report details the medical history of a 12-year-old boy diagnosed with CACP syndrome, following the identification of a novel homozygous frameshift variant in the PRG4 gene. The patient first exhibited symptoms at 10 days of age with respiratory distress due to pleural effusion and later underwent pericardiectomy for significant pericardial effusion. At age 2, progressive joint effusion led to an initial diagnosis of juvenile idiopathic arthritis. Despite receiving treatment modalities such as non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, and corticosteroids, the patient experienced minimal improvement. The persistence of progressive joint manifestations, coupled with a lack of favorable response to treatment, prompted further evaluations, which ultimately confirmed the diagnosis of CACP syndrome. This case illustrates diagnostic challenges and rare early cardiac involvement. It discusses the differential diagnosis from juvenile idiopathic arthritis and skeletal dysplasia, as well as the role of genetic testing in unresolved cases.